Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer

The combination of paclitaxel, carboplatin and cetuximab (PCC) is efficacious in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). The current study assessed the incidence of grade 3/4 (G3/4) toxicity for patients receiving weekly or 3-weekly PCC for R/M...

Descripción completa

Detalles Bibliográficos
Autores principales: Geraghty, Leeann, Schultz, Thomas E., Hoffman, Sarah E., Porter, Kyle, Issa, Majd, Karivedu, Vidhya, Bonomi, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506685/
https://www.ncbi.nlm.nih.gov/pubmed/34650807
http://dx.doi.org/10.3892/mco.2021.2403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506685/
https://www.ncbi.nlm.nih.gov/pubmed/34650807
http://dx.doi.org/10.3892/mco.2021.2403

Ejemplares similares